Tempus AI Inc

Tempus AI Inc. files Rule 144 SEC disclosure—detailing Feb‑Mar 2026 share sales, $9.16 bn cap, negative P/E, and market‑price trends for investors.

Tempus AI’s AI platform shows real‑world cardiac benefits yet faces shrinking analyst targets, as investors weigh clinical success against uncertain revenue growth.

ARK Invest’s small stake in Tempus AI signals interest in its gene‑editing and precision‑medicine focus, despite current losses, and may hint at future growth opportunities.

Tempus AI Inc is facing legal challenges and financial scrutiny as it prepares to report its Q2 earnings, with its stock price and market capitalization reflecting investor concerns.

Tempus AI Inc. faces financial and legal challenges, including a securities fraud lawsuit, as it prepares to unveil its quarterly financial results amidst a mixed market sentiment and uncertain valuation.

Tempus AI Inc. is facing two class action lawsuits alleging securities fraud, claiming the company made false and misleading statements to investors between August 2024 and May 2025.

Tempus AI Inc’s stock price plummeted 19.23% after a scathing report from Spruce Point Capital Management, casting a shadow over the company’s valuation, business model, and financial transparency.